Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients

References

• GuimaraesM, BugalhoA, OliveiraAS, MoitaJ, MarquesA. COPD control: can a consensus be found? Rev Port Pneumol. 2016;22(3):167–176. doi:10.1016/j.rppnen.2016.01.00427004479
   PubMed Web of Science ®Google Scholar
• SeemungalTA, DonaldsonGC, BhowmikA, JeffriesDJ, WedzichaJA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(5):1608–1613. doi:10.1164/ajrccm.161.5.990802210806163
   PubMed Web of Science ®Google Scholar
• DonaldsonGC, SeemungalTA, BhowmikA, WedzichaJA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852. doi:10.1136/thorax.57.10.84712324669
   PubMed Web of Science ®Google Scholar
• SeemungalTA, DonaldsonGC, PaulEA, BestallJC, JeffriesDJ, WedzichaJA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418–1422. doi:10.1164/ajrccm.157.5.97090329603117
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease 2018. 2018 Available from: http://goldcopd.org/. Accessed 713, 2020.
   Google Scholar
• BertensLC, ReitsmaJB, MoonsKG, et al. Development and validation of a model to predict the risk of exacerbations in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:493–499. doi:10.2147/COPD.S4960924143086
   PubMed Web of Science ®Google Scholar
• HolgateST. Priorities for respiratory research in the UK. Thorax. 2007;62(1):5–7. doi:10.1136/thx.2006.07388217189530
   PubMed Web of Science ®Google Scholar
• HurstJR, VestboJ, AnzuetoA, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa090988320843247
   PubMed Web of Science ®Google Scholar
• AlivertiA, RodgerK, DellacaRL, et al. Effect of salbutamol on lung function and chest wall volumes at rest and during exercise in COPD. Thorax. 2005;60(11):916–924. doi:10.1136/thx.2004.03793715994253
   PubMed Web of Science ®Google Scholar
• O’DonnellDE, LamM, WebbKA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160(2):542–549. doi:10.1164/ajrccm.160.2.990103810430726
   PubMed Web of Science ®Google Scholar
• PapiA, VestboJ, FabbriL, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X29429593
   PubMed Web of Science ®Google Scholar
• CalverleyPMA, AnzuetoAR, CarterK, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6(5):337–344. doi:10.1016/S2213-2600(18)30102-429605624
   PubMed Web of Science ®Google Scholar
• WedzichaJA, BanerjiD, ChapmanKR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. doi:10.1056/NEJMoa151638527181606
   PubMed Web of Science ®Google Scholar
• WedzichaJA, DecramerM, FickerJH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199–209. doi:10.1016/S2213-2600(13)70052-324429126
   PubMed Web of Science ®Google Scholar
• JonesPW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002;19(3):398–404. doi:10.1183/09031936.02.0006370211936514
   PubMed Web of Science ®Google Scholar
• JonesPW, QuirkFH, BaveystockCM. The St George’s respiratory questionnaire. Respir Med. 1991;85(Suppl B):25–31; discussion 33–27. doi:10.1016/S0954-6111(06)80166-6
   Web of Science ®Google Scholar
• KonSS, CanavanJL, JonesSE, et al. Minimum clinically important difference for the COPD assessment test: a prospective analysis. Lancet Respir Med. 2014;2(3):195–203. doi:10.1016/S2213-2600(14)70001-324621681
   PubMed Web of Science ®Google Scholar
• AyoraAF, SolerLM, GaschAC. Analysis of two questionnaires on quality of life of chronic obstructive pulmonary disease patients. Rev Lat Am Enfermagem. 2019;27:e3148. doi:10.1590/1518-8345.2624.314831340341
   PubMed Web of Science ®Google Scholar
• Morishita-KatsuM, NishimuraK, TaniguchiH, et al. The COPD assessment test and St George’s respiratory questionnaire: are they equivalent in subjects with COPD? Int J Chron Obstruct Pulmon Dis. 2016;11:1543–1551. doi:10.2147/COPD.S10494727462150
   PubMed Web of Science ®Google Scholar
• FrentSM, ChapmanKR, LarbigM, et al. Capturing exacerbations of chronic obstructive pulmonary disease with EXACT. A subanalysis of FLAME. Am J Respir Crit Care Med. 2019;199(1):43–51. doi:10.1164/rccm.201801-0038OC30019939
   PubMed Web of Science ®Google Scholar
• DonohueJF, JonesPW, BartelsC, et al. Correlations between FEV1 and patient-reported outcomes: a pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2018;49:11–19. doi:10.1016/j.pupt.2017.12.00529277690
   PubMed Web of Science ®Google Scholar
• CalverleyPM, PostmaDS, AnzuetoAR, et al. Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2016;11:381–390. doi:10.2147/COPD.S9330326952309
   PubMed Web of Science ®Google Scholar
• BatemanED, FergusonGT, BarnesN, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484–1494. doi:10.1183/09031936.0020021223722616
   PubMed Web of Science ®Google Scholar
• BuhlR, GessnerC, SchuermannW, et al. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. Thorax. 2015;70(4):311–319. doi:10.1136/thoraxjnl-2014-20634525677679
   PubMed Web of Science ®Google Scholar
• SinghD, D’UrzoAD, ChuecosF, MunozA, Garcia GilE. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. Respir Res. 2017;18(1):106. doi:10.1186/s12931-017-0583-028558833
   PubMed Web of Science ®Google Scholar
• SinghD, Maleki-YazdiMR, TombsL, IqbalA, FahyWA, NayaI. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11:1413–1424. doi:10.2147/COPD.S10161227445468
   PubMed Web of Science ®Google Scholar
• AnzuetoAR, VogelmeierCF, KostikasK, et al. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1325–1337. doi:10.2147/COPD.S13330728496316
   PubMed Web of Science ®Google Scholar
• GreulichT, KostikasK, GagaM, et al. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. Int J Chron Obstruct Pulmon Dis. 2018;13:1229–1237. doi:10.2147/COPD.S15973229713156
   PubMed Web of Science ®Google Scholar
• Ian NayaLT, MullerovaH, ComptonC, JonesP. Long-term outcome following first clinically important deterioration in COPD. Eur Respir J. 2016;46:PA304.
   Google Scholar
• MakeBJ, ErikssonG, CalverleyPM, et al. A score to predict short-term risk of COPD exacerbations (SCOPEX). Int J Chron Obstruct Pulmon Dis. 2015;10:201–209. doi:10.2147/COPD.S6958925670896
   PubMed Web of Science ®Google Scholar